Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group..

J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.

2.

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G.

Clin Cancer Res. 2005 Jul 15;11(14):5223-32. Review.

4.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3..

J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702.

5.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G, et al.

J Clin Oncol. 1999 Nov;17(11):3461-7. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702. J Clin Oncol 2000 Jul;18(13):2644. J Clin Oncol. 2007 Mar 20;25(9):1154.

PMID:
10550143
6.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Review.

PMID:
24321502
7.

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR.

J Clin Oncol. 2004 Feb 1;22(3):537-56. Erratum in: J Clin Oncol. 2004 Aug 1;22(15):3205.

PMID:
14752077
8.

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer.

Mulders PF, Schalken JA.

Prostate Cancer Prostatic Dis. 2009;12(3):241-6. doi: 10.1038/pcan.2009.25. Review.

PMID:
19597531
9.

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.

Scher HI, Morris MJ, Basch E, Heller G.

J Clin Oncol. 2011 Sep 20;29(27):3695-704. doi: 10.1200/JCO.2011.35.8648. Review.

10.

Trial design for metastatic castration-resistant prostate cancer.

Sonpavde G, Fleming MT, Hutson TE, Galsky MD.

J Clin Oncol. 2008 Jul 20;26(21):3647-8; author reply 3648-9. doi: 10.1200/JCO.2008.17.1140. No abstract available.

PMID:
18640946
11.

Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI.

Eur Urol. 2009 Aug;56(2):237-44. doi: 10.1016/j.eururo.2009.03.073.

13.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Spanish.

PMID:
21757258
14.

Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.

Berry W, Eisenberger M.

Oncologist. 2005;10 Suppl 3:30-9. Review.

15.
16.

Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.

Oefelein MG, Agarwal PK, Resnick MI.

J Urol. 2004 Apr;171(4):1525-8.

PMID:
15017212
17.
18.

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG.

Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Review.

19.
20.

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ.

Urology. 2003 Dec 29;62 Suppl 1:128-33. Review.

PMID:
14747050

Supplemental Content

Support Center